The second quarter brings updates for Scholar Rock, Alnylam and Dicerna, among others.
Sobi picking up rights to Apellis’s complement factor C3 inhibitor adds to earlier deals focused on C5, D and anti-FcRn antibodies.
A miss for Roche’s Akt inhibitor in advanced breast cancer leaves questions over population and combination.
Licensing deal could enable bundling of antipsychotics with management technology.
Cardiac safety threatens to derail the company’s new anaemia pill, but should rival Fibrogen be celebrating?
Coronavirus aside, biotech companies including Akebia, Blueprint, Genfit and TG Therapeutics are set for some important data readouts in the next couple of months.
The failures of two bought-in assets leave a third hopelessly exposed to the Covid-19 lockdown.